Darzalex (daratumumab) and risk of reactivation of hepatitis B virus: Dear Healthcare Professional letter

Letter warns of risk of hepatitis B virus reactivation (HBVR), including some fatalities, in patients treated with daratumumab. All patients should be screened for HBV before treatment. Advice is provided on how to manage patients with positive HBV serology and HBVR.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news